πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

48 results for β€œAllogene” Clear

  1. cemacabtagene ansegedleucel

    Allogene Therapeutics

    Large B-cell Lymphoma

    phase 2 gene therapy active

    1 trial

  2. A Phase 1 Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants with Severe, Refractory Autoimmune Diseases

    Bristol-Myers Squibb / Pfizer EEIG

    Systemic Sclerosis, Idiopathic Inflammatory Myopathy, Rheumatoid Arthritis, Systemic Lupus Erythematosus

    phase 1 other active

    1 trial

  3. ALLO-316

    Allogene Therapeutics

    Advanced/Metastatic Clear Cell Renal Cell Carcinoma

    phase 1 gene therapy active

    1 trial

  4. ALLO-329

    Allogene Therapeutics

    Systemic Lupus Erythematosus (With and Without Nephritis)

    phase 1 gene therapy active

    1 trial

  5. ALLO-501

    Allogene Therapeutics

    Relapsed/Refractory Large B Cell Lymphoma

    phase 1 gene therapy completed

    1 trial

  6. ALLO-715

    Allogene Therapeutics

    Relapsed/Refractory Multiple Myeloma

    phase 1 gene therapy completed

    1 trial

  7. Allogeneic (MSC's) Application to the Burn Wounds

    United Therapeutics Europe Ltd

    Skin Burn Degree Second

    phase 1 mab completed

    1 trial

  8. Allogeneic CD19/BCMA-targeted CAR-Ξ³Ξ΄T cell injection

    China SXT Pharmaceuticals

    Refractory/Relapsed Systemic Lupus Erythematosus

    phase 1 mab active

    1 trial

  9. Allogeneic Cardiosphere-Derived Cells (CDCs)

    CAPRICOR THERAPEUTICS, INC.

    Dilated Cardiomyopathy (DCM)

    phase 1 mab active

    1 trial

  10. Allogeneic MSC

    United Therapeutics Europe Ltd

    Mesenchymal Stromal Cells

    phase 1 mab completed

    1 trial

  11. Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted Ξ³Ξ΄ T Cells (CTM-N2D)

    CytoMed Therapeutics Ltd

    Cancer

    phase 1 mab active

    1 trial

  12. Allogeneic anti-CD7 CAR-T cells (BEAM-201)

    Beam Therapeutics

    T-Cell Acute Lymphoblastic Leukemia/Lymphoma

    phase 1 mab active

    1 trial

  13. An open label, phase 1 study to evaluate the safety, feasibility and immunogenicity of an allogeneic, cell-based vaccine (VIDIDENCEL) in high grade serous ovarian cancer patients after primary treatment (ALISON)

    Disc Medicine

    High grade serous ovarian cancer

    phase 1 other active

    1 trial

  14. CD123+CLL-1 dual-target CAR-T cells sequential infusion CD7 CAR-T cells and bridging to allogeneic

    China SXT Pharmaceuticals

    AML - Acute Myeloid Leukemia

    phase 1 mab active

    1 trial

  15. CD19 and BCMA-targeted allogeneic CAR-T cells

    First Tracks Biotherapeutics

    Refractory Immune-mediated Platelet Transfusion Refractoriness

    phase 1 gene therapy active

    1 trial

  16. CLADRIBINE DOSE ESCALATION IN CONDITIONING REGIMEN PRIOR TO ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (Allo-HSCT) FOR REFRACTORY ACUTE LEUKEMIA AND MYELODYSPLASTIC SYNDROMES

    Institut fΓΌr biomedizinische Analytik NMR-Imaging GmbH

    Acute leukemia and myelodysplastic syndromes

    phase 1 other active

    1 trial

  17. Cardiac safety of treosulfan chemotherapy prior to stem cell transplantation in patients with leukemia.

    Medac Gesellschaft fuer klinische Spezialpraeparate mbH

    Subjects with AML ( Acute myeloid leukaemia) or MDS (Myelodysplastic syndrome) undergoing allogeneic hematopoietic stem cell transplantation

    phase 1 other active

    1 trial

  18. Ex-vivo expanded allogeneic Ξ³Ξ΄ T cells

    China SXT Pharmaceuticals

    AML (Acute Myelogenous Leukemia)

    phase 1 mab active

    1 trial

  19. Ex-vivo expanded allogeneic Ξ³Ξ΄T cells

    China SXT Pharmaceuticals

    Non-Hodgkin's Lymphoma (NHL)

    phase 1 mab active

    1 trial

  20. JYEST Cell Injection Infusion

    China SXT Pharmaceuticals

    Prevention of EBV Infection After Allogeneic Hematopoietic Stem Cell Transplantation

    phase 1 mab active

    1 trial

  21. Vancomycin Pre-Treatment

    Seres Therapeutics

    Allogeneic Hematopoietic Stem Cell Transplantation

    phase 1 small molecule completed

    1 trial

  22. Virus-specific T-cell Immunity for the Treatment of Some Resistant Viral Infections After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

    Istituto Gentili S.r.l.

    Patients who have received an allogeneic haematopoietic stem cell transplant and who have developed post-transplant viral reactivation (CMV, Adenovirus, EBV) resistant to pharmacological therapies.

    phase 1 other active

    1 trial

  23. haploid allogeneic NK cell therapy

    China SXT Pharmaceuticals

    Acute Myeloid Leukemia

    phase 1 mab active

    1 trial

  24. Goserelin

    First Tracks Biotherapeutics

    Allogeneic Haematopoietic Stem Cell Transplantation

    small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources